Works by Goldschmidt, Neta

Results: 58
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant.

    Published in:
    2010
    By:
    • Koren-Michowitz M;
    • le Coutre P;
    • Duyster J;
    • Scheid C;
    • Panayiotidis P;
    • Prejzner W;
    • Rowe JM;
    • Schwarz M;
    • Goldschmidt N;
    • Nagler A;
    • Koren-Michowitz, Maya;
    • le Coutre, Philipp;
    • Duyster, Justus;
    • Scheid, Christof;
    • Panayiotidis, Panayiotis;
    • Prejzner, Witold;
    • Rowe, Jacob M;
    • Schwarz, Michaela;
    • Goldschmidt, Neta;
    • Nagler, Arnon
    Publication type:
    journal article
    11

    Activity and Tolerability of Nilotinib.

    Published in:
    Cancer (0008543X), 2010, v. 116, n. 19, p. 4564, doi. 10.1002/cncr.25351
    By:
    • Koren-Michowitz, Maya;
    • le Coutre, Philipp;
    • Duyster, Justus;
    • Scheid, Christof;
    • Panayiotidis, Panayiotis;
    • Prejzner, Witold;
    • Rowe, Jacob M.;
    • Schwarz, Michaela;
    • Goldschmidt, Neta;
    • Nagler, Arnon
    Publication type:
    Article
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30

    Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/ CT is beneficial: a prospective multicentre trial of 355 patients.

    Published in:
    British Journal of Haematology, 2017, v. 178, n. 5, p. 709, doi. 10.1111/bjh.14734
    By:
    • Dann, Eldad J.;
    • Bairey, Osnat;
    • Bar‐Shalom, Rachel;
    • Mashiach, Tanya;
    • Barzilai, Elinor;
    • Kornberg, Abraham;
    • Akria, Luiza;
    • Tadmor, Tamar;
    • Filanovsky, Kalman;
    • Abadi, Uri;
    • Kagna, Olga;
    • Ruchlemer, Rosa;
    • Abdah‐Bortnyak, Roxolyana;
    • Goldschmidt, Neta;
    • Epelbaum, Ron;
    • Horowitz, Netanel A.;
    • Lavie, David;
    • Ben‐Yehuda, Dina;
    • Shpilberg, Ofer;
    • Paltiel, Ora
    Publication type:
    Article
    31
    32
    33

    Risk factors and outcomes of COVID‐19 in adult patients with hematological malignancies: A single‐center study showing lower than expected rates of hospitalization and mortality.

    Published in:
    European Journal of Haematology, 2023, v. 111, n. 1, p. 135, doi. 10.1111/ejh.13977
    By:
    • Aumann, Shlomzion;
    • Tsubary, Uria;
    • Nachmias, Boaz;
    • Ben Yehuda, Dina;
    • Lavie, David;
    • Goldschmidt, Neta;
    • Vainstein, Vladimir;
    • Libster, Diana;
    • Saban, Revital;
    • Shaulov, Adir;
    • Israel, Sarah;
    • Avni, Batia;
    • Grisariu, Sigal;
    • Bdolah‐Amram, Tali;
    • Gatt, Moshe;
    • Zimran, Eran
    Publication type:
    Article
    34

    Predictive value of the CLL‐IPI in CLL patients receiving chemo‐immunotherapy as first‐line treatment.

    Published in:
    European Journal of Haematology, 2018, v. 101, n. 5, p. 703, doi. 10.1111/ejh.13149
    By:
    • Gentile, Massimo;
    • Shanafelt, Tait D.;
    • Mauro, Francesca Romana;
    • Reda, Gianluigi;
    • Rossi, Davide;
    • Laurenti, Luca;
    • Del Principe, Maria Ilaria;
    • Cutrona, Giovanna;
    • Angeletti, Ilaria;
    • Coscia, Marta;
    • Herishanu, Yair;
    • Chiarenza, Annalisa;
    • Molica, Stefano;
    • Ciolli, Stefania;
    • Goldschmidt, Neta;
    • Angrilli, Francesco;
    • Giordano, Annamaria;
    • Rago, Angela;
    • Bairey, Osnat;
    • Tripepi, Giovanni
    Publication type:
    Article
    35

    Outcomes of second‐line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.

    Published in:
    European Journal of Haematology, 2018, v. 101, n. 3, p. 399, doi. 10.1111/ejh.13129
    By:
    • Joffe, Erel;
    • Goldschmidt, Neta;
    • Bairey, Osnat;
    • Fineman, Riva;
    • Ruchlemer, Rosa;
    • Rahimi‐Levene, Naomi;
    • Shvidel, Lev;
    • Greenbaum, Uri;
    • Aviv, Ariel;
    • Tadmor, Tamar;
    • Braester, Andrea;
    • Arad, Ariela;
    • Polliack, Aaron;
    • Herishanu, Yair;
    • The Israeli CLL Study Group
    Publication type:
    Article
    36
    37
    38
    39
    40
    41

    Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real‐World" study.

    Published in:
    American Journal of Hematology, 2023, v. 98, n. 2, p. E24, doi. 10.1002/ajh.26779
    By:
    • Levi, Shai;
    • Bronstein, Yotam;
    • Goldschmidt, Neta;
    • Morabito, Fortunato;
    • Ziv‐Baran, Tomer;
    • Del Poeta, Giovanni;
    • Bairey, Osnat;
    • Del Principe, Maria Ilaria;
    • Fineman, Riva;
    • Mauro, Francesca Romana;
    • Gutwein, Odit;
    • Reda, Gianluigi;
    • Ruchlemer, Rosa;
    • Sportoletti, Paolo;
    • Laurenti, Luca;
    • Shvidel, Lev;
    • Coscia, Marta;
    • Tadmor, Tamar;
    • Varettoni, Marzia;
    • Aviv, Ariel
    Publication type:
    Article
    42
    43
    44
    45
    46

    Richter's transformation to diffuse large B-cell lymphoma: A retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group.

    Published in:
    American Journal of Hematology, 2014, v. 89, n. 11, p. E218, doi. 10.1002/ajh.23826
    By:
    • Tadmor, Tamar;
    • Shvidel, Lev;
    • Bairey, Osnat;
    • Goldschmidt, Neta;
    • Ruchlemer, Rosa;
    • Fineman, Riva;
    • Rahimi-Levene, Naomi;
    • Herishanu, Yair;
    • Yuklea, Mona;
    • Arad, Ariela;
    • Aviv, Ariel;
    • Polliack, Aaron
    Publication type:
    Article
    47
    48
    49
    50